Literature DB >> 9270664

Effect of high-dose intravenous immunoglobulin on serum chemistry, hematology, and lymphocyte subpopulations: assessments based on controlled treatment trials in patients with neurological diseases.

B M Koffman1, M C Dalakas.   

Abstract

The effect of intravenous immunoglobulin (IVIG) on various laboratory values was measured immediately before and after completion of serial monthly infusions of IVIG (2 g/kg) or an equal volume of placebo over 3-12 months, in 46 patients with neuromuscular diseases participating in controlled trials. Hematological, lymphocyte subpopulation, and chemistry values were analyzed and compared. After IVIG, but not placebo, a 34% reduction in lymphocytes was noted in 44/46 patients with a selective reduction of the T cells, but not the B or IL2R-positive cells. Counts returned to baseline within 30 days. Creatine kinase levels decreased by 23% and sedimentation rate increased by 275% after IVIG infusion. A nondilutional, artifactual, hyponatremia and hypomagnesemia was noted with IVIG but not placebo. We conclude that IVIG affects a variety of serum chemistry and hematological values either directly or artifactually by interfering with the laboratory method used for the assays. Transient lymphopenia is consistently seen, and may play a role in the immunomodulating effect of IVIG.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9270664     DOI: 10.1002/(sici)1097-4598(199709)20:9<1102::aid-mus2>3.0.co;2-c

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  14 in total

1.  Pseudohyponatremia: does it matter in current clinical practice?

Authors:  Gheun-Ho Kim
Journal:  Electrolyte Blood Press       Date:  2006-11

2.  Use of intravenous immunoglobulin in critically ill patients.

Authors:  Summer Donovan; Gonzalo M L Bearman
Journal:  Curr Infect Dis Rep       Date:  2014-12       Impact factor: 3.725

Review 3.  Intravenous immunoglobulin in neurology--mode of action and clinical efficacy.

Authors:  Jan D Lünemann; Falk Nimmerjahn; Marinos C Dalakas
Journal:  Nat Rev Neurol       Date:  2015-01-06       Impact factor: 42.937

4.  Multicenter study to determine antibody concentrations and assess the safety of administration of INH-A21, a donor-selected human Staphylococcal immune globulin, in low-birth-weight infants.

Authors:  Edmund V Capparelli; Barry T Bloom; Tom J Kueser; David G Oelberg; Ellen M Bifano; Robert D White; Robert L Schelonka; Stephen A Pearlman; Joseph Patti; Seth V Hetherington
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

Review 5.  Intravenous immunoglobulins for treatment of connective tissue diseases in dermatology.

Authors:  Lyubomir A Dourmishev; Dimitrina V Guleva; Ljubka G Miteva
Journal:  Wien Med Wochenschr       Date:  2017-09-01

Review 6.  Paraneoplastic syndromes: an approach to diagnosis and treatment.

Authors:  Lorraine C Pelosof; David E Gerber
Journal:  Mayo Clin Proc       Date:  2010-09       Impact factor: 7.616

Review 7.  Efficacy of Intravenous Immunoglobulin in Neurological Diseases.

Authors:  Jan D Lünemann; Isaak Quast; Marinos C Dalakas
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

8.  True hyponatremia secondary to intravenous immunoglobulin.

Authors:  Minhtri K Nguyen; Anjay Rastogi; Ira Kurtz
Journal:  Clin Exp Nephrol       Date:  2006-06       Impact factor: 2.617

9.  A Multicentre Study on the Efficacy, Safety and Pharmacokinetics of IqYmune®, a Highly Purified 10% Liquid Intravenous Immunoglobulin, in Patients with Primary Immune Deficiency.

Authors:  Gergely Krivan; Ludmila Chernyshova; Larysa Kostyuchenko; Andrzej Lange; Zoltan Nyul; Beata Derfalvi; Jacek Musial; Anne Bellon; Martin Kappler; Alain Sadoun; Ewa Bernatowska
Journal:  J Clin Immunol       Date:  2017-07-15       Impact factor: 8.317

Review 10.  Therapeutic Potential of HLA-I Polyreactive mAbs Mimicking the HLA-I Polyreactivity and Immunoregulatory Functions of IVIg.

Authors:  Mepur H Ravindranath; Fatiha El Hilali; Edward J Filippone
Journal:  Vaccines (Basel)       Date:  2021-06-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.